Chemo-mediated transcriptional reprogramming in ovarian cancer
Chemo-mediated transcriptional reprogramming in ovarian cancer
批准号:
10709477
负责人:
Mazhar Adli
金额:
$45.24万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-23 至 2027-08-31
关键词:
ATAC-seqAcuteArchitectureBiologyCarboplatinCarcinomaCell ReprogrammingCellsCessation of lifeChemoresistanceChromatinCisplatinClinicalClustered Regularly Interspaced Short Palindromic RepeatsDNA DamageDNA RepairDNA Sequence AlterationDataDoseEnhancersEpigenetic ProcessGatekeepingGene ExpressionGenesGeneticGenetic TranscriptionGenomeGenomicsGoalsGrowthImmunocompetentIn VitroMalignant - descriptorMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMapsMeasuresMediatingModelingMolecularNon-MalignantOperative Surgical ProceduresOvarian Serous AdenocarcinomaPathway interactionsPatientsPlatinumPlayPopulationPrimary NeoplasmPrognosisPublishingRecurrenceRelapseRepressionResearchResistanceRoleSamplingSerousTechnologyTestingTherapeuticTumor DebulkingTumor ImmunityTumor TissueUp-RegulationWorkarginine methyltransferasecancer cellcancer subtypescancer therapychemotherapyclinically relevantcohortcombinatorialcomparativeepigenomeepigenomicsgenome editinggenome-wideimprovedin vivoinsightmortalitynon-geneticnovelnovel therapeutic interventionprogrammed cell death ligand 1programsresponsescreeningsingle-cell RNA sequencingstem-like celltherapeutic targettherapeutically effectivetooltranscription factortranscriptional reprogrammingtranscriptometranscriptomic profilingtranscriptomicstumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
High-grade serous carcinoma (HGSC) is the most aggressive OC subtype that accounts for 80% of OC-related
deaths. Rapid emergence of platinum (Pt)-resistance is the main reason for this mortality. Despite initial
response to surgery plus chemotherapy, tumors relapse and rapidly become chemoresistant in 80% of patients.
Although few genetic mutations have been associated with chemoresistance, in a large fraction of tumors, drivers
of the chemoresistance's rapid emergence are unknown. Here we propose that non-genetic mechanisms play
an important part in regulating cellular transition to a resistant state in high grade serous ovarian cancer. We
will tackle the emergence of Pt resistance from a global transcriptional reprogramming point of view. Our
published and preliminary findings support the hypothesis that Pt resistance emerges from therapy-induced
population-level epigenomic and transcriptional reprogramming. Through integrative analysis of epigenomes
and transcriptomes of multiple naïve and cisplatin-resistant isogenic cells, we identified resistant-state specific
super-enhancers and their target transcription factor networks (TFN). The first aim employs cutting edge
genomic mapping and manipulation technologies including single cell-level CRISPR-perturbations followed by
transcriptome profiling to identify which TFs and TF-combinations are necessary to reprogram naïve cells into
the resistant state. The second aim investigates a novel combinatorial target to achieve synthetic lethality with
carboplatin in HGSOC. The findings from this proposal will provide new mechanistic insight into the role of key
transcription factor network that govern platinum resistance in ovarian cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemo-mediated transcriptional reprogramming in ovarian cancer
-
批准号:10346704
-
项目类别:
-
资助金额:$47.23万
-
财政年份:2022
-
负责人:Mazhar Adli
-
依托单位:
Molecular and cellular characterization of essential human genes.
-
批准号:10708906
-
项目类别:
-
资助金额:$163.13万
-
财政年份:2022
-
负责人:Mazhar Adli
-
依托单位:
Molecular and cellular characterization of essential human genes.
-
批准号:10517781
-
项目类别:
-
资助金额:$166.98万
-
财政年份:2022
-
负责人:Mazhar Adli
-
依托单位:
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
-
批准号:10166791
-
项目类别:
-
资助金额:$41.39万
-
财政年份:2017
-
负责人:Mazhar Adli
-
依托单位:
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
-
批准号:9330488
-
项目类别:
-
资助金额:$42.92万
-
财政年份:2017
-
负责人:Mazhar Adli
-
依托单位:
海外基金